Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 12,322 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 12,322 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total value of $49,904.10. Following the completion of the transaction, the chief financial officer now owns 1,446,322 shares of the company’s stock, valued at $5,857,604.10. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

William Garrett Gray also recently made the following trade(s):

• On Thursday, February 6th, William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $3.67, for a total value of $271,983.70.

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock remained flat at $4.04 during trading hours on Thursday. The company’s stock had a trading volume of 3,954,642 shares, compared to its average volume of 1,144,292. Checkpoint Therapeutics, Inc. has a 1-year low of $1.38 and a 1-year high of $4.50. The stock has a 50-day simple moving average of $3.40 and a 200-day simple moving average of $3.30. The stock has a market cap of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.21.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Friday, March 28th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The company had revenue of $0.04 million for the quarter. Analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of hedge funds have recently modified their holdings of CKPT. Tower Research Capital LLC TRC increased its holdings in Checkpoint Therapeutics by 157.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock valued at $34,000 after purchasing an additional 6,486 shares during the period. Ameriflex Group Inc. bought a new stake in shares of Checkpoint Therapeutics in the 4th quarter worth approximately $32,000. PUREfi Wealth LLC purchased a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at approximately $32,000. SBI Securities Co. Ltd. bought a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at approximately $32,000. Finally, Stifel Financial Corp bought a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. HC Wainwright reissued a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. Lake Street Capital reaffirmed a “hold” rating and set a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, D. Boral Capital reissued a “buy” rating and issued a $4.80 price target on shares of Checkpoint Therapeutics in a research note on Monday.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.